Understanding how amphetamines affect the brain's dopamine system
The Role of the Dopamine Transporter in Psychostimulant Abuse
This research aims to understand how amphetamines change brain chemistry to cause addiction, hoping to find new ways to help people struggling with psychostimulant abuse.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10994659 on NIH RePORTER |
What this research studies
Amphetamines are medicines for some conditions, but they can also be misused, leading to serious problems. When someone takes amphetamines, they cause a chemical called dopamine to increase in the brain, which is linked to their stimulating effects and potential for abuse. This increase happens because amphetamines make a specific protein, the dopamine transporter (DAT), work in reverse, releasing more dopamine. Our goal is to uncover the exact steps amphetamines take to reverse the DAT and how this affects brain function, which could lead to new treatments for amphetamine abuse.
Who could benefit from this research
Good fit: This foundational research is for anyone affected by amphetamine abuse, as it seeks to understand the core mechanisms that could lead to future therapies.
Not a fit: Patients not affected by psychostimulant abuse would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to the development of new medications that specifically block the harmful effects of amphetamines on the brain, offering a new treatment for psychostimulant abuse.
How similar studies have performed: Previous work by this team and others has shown that a specific part of the dopamine transporter is crucial for how amphetamines cause dopamine release, providing a strong foundation for this current investigation.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Galli, Aurelio — University of Alabama at Birmingham
- Study coordinator: Galli, Aurelio
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.